A July 17 response deadline requires documentation of trial-site governance in China, emphasizing due diligence, data protection controls, and monitoring of compliance at Xinjiang and PLA-affiliated ...

Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...

Arthur G. Cook is Principal, ZS Associates.

Resilient field models emphasize continuous territory coverage via agile deployment, blending scalable virtual reach with ...

It was a jarring experience that stemmed from a startlingly common misconception: that adults don't get T1D; however, she is ...

In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic ...

For pharmaceutical executives, the transition from just extending to fully optimizing life is a defining commercial ...

Approval establishes sacituzumab govitecan as a first-line option across PD-L1 strata, including monotherapy when checkpoint inhibitors are unsuitable and combination therapy for PD-L1 CPS ≥10 tumors.

"Direct-to-patient isn't merely a new distribution channel; it's a strategic imperative for brand differentiation and market access. When executed well, it enables manufacturers to expand patient ...

A $105 million upfront payment supports joint discovery of first-in-class precision medicines, with potential milestones totaling $1.8 billion linked to development, regulatory, and commercial ...

In today's Pharmaceutical Executive Daily, Eli Lilly and Abbisko Therapeutics announce a new strategic research collaboration in which Abbisko will leverage its early-stage drug discovery platform to ...

CHMP recommended EU marketing authorization for pirtobrutinib in adult CLL across all therapy lines, regardless of prior BTK inhibitor treatment history. BRUIN CLL-313 and CLL-314 supported meaningful ...